CSPC Innovation Pharmaceutical: Regarding this trade, it is expected to constitute a significant asset restructuring under Article 12 of the "Management Measures for Major Asset Restructuring of Listed Companies", but it does not constitute a case of restructuring for listing under Article 13.

SZSI · Jul 24

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

新诺威：关于本次交易预计构成《上市公司重大资产重组管理办法》第十二条规定的重大资产重组，但不构成第十三条规定的重组上市情形的说明

CSPC Innovation Pharmaceutical: Regarding this trade, it is expected to constitute a significant asset restructuring under Article 12 of the "Management Measures for Major Asset Restructuring of Listed Companies", but it does not constitute a case of restructuring for listing under Article 13.

Risk Disclaimer

Statement